Skip to main content
. 2022 Sep 22;8(11):1663–1667. doi: 10.1001/jamaoncol.2022.4109

Figure 1. Pembrolizumab Dosing Practices After FDA Approval of Extended-Interval Dosing.

Figure 1.

A and B, the x-axis corresponds to the month and year of the study. C and D, the x-axis corresponds to time since incident pembrolizumab. FDA refers to the US Food and Drug Administration.